The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly

Ho Namkoong; Youjyu Kameyama; Hiroyuki Yasuda; Sohei Nakayama; Hiroshi Kaneko; Chieko Kawashima; Tomoko Terajima; Kayoko Maezawa; Takeshi Hayashi; Mitsuru Sandoh; Makoto Ishii; Sadatomo Tasaka; Akiko Kanayama; Intetsu Kobayashi; Tomoko Betsuyaku; Junko Kizu; Satoshi Iwata; Yoshitake Sato; Naoki Hasegawa

doi:10.1016/j.jiac.2013.12.010

The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly

Ho Namkoong, Youjyu Kameyama, Hiroyuki Yasuda, Sohei Nakayama, Hiroshi Kaneko, Chieko Kawashima, Tomoko Terajima, Kayoko Maezawa, Takeshi Hayashi, Mitsuru Sandoh, Makoto Ishii, Sadatomo Tasaka, Akiko Kanayama, Intetsu Kobayashi, Tomoko Betsuyaku, Junko Kizu, Satoshi Iwata, Yoshitake Sato, Naoki Hasegawa

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Biapenem has been widely used to treat bacterial pneumonia; however, there is little information concerning its efficacy and safety in elderly patients. Based on pharmacokinetic-pharmacodynamic theory, administration of biapenem thrice rather than twice daily would be expected to be more effective because of longer time above the minimum inhibitory concentration. In this study, we aimed to evaluate the efficacy, safety, and pharmacokinetics of biapenem (300 mg) administered thrice daily in pneumonic patients aged 65 years or older. Biapenem was effective in 22 of 25 patients, as assessed by the improvement in clinical symptoms and/or the eradication of the causative organisms, and caused no serious adverse events. The pharmacokinetic profile was established based on simulations using a modeling program. Among 17 patients whose causative organisms were detected, time above the minimum inhibitory concentration was estimated to be 100% in 16 patients, all of whom showed clinical improvement. The results of this study confirmed the efficacy and safety of 300 mg of biapenem administered thrice daily for the treatment of pneumonia in elderly patients.

Original language	English
Pages (from-to)	356-360
Number of pages	5
Journal	Journal of Infection and Chemotherapy
Volume	20
Issue number	6
DOIs	https://doi.org/10.1016/j.jiac.2013.12.010
Publication status	Published - 2014 Jun

Keywords

Biapenem
Elderly patients
Pharmacokinetics-pharmacodynamics (PK-PD)
Pneumonia

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jiac.2013.12.010

Cite this

Namkoong, H., Kameyama, Y., Yasuda, H., Nakayama, S., Kaneko, H., Kawashima, C., Terajima, T., Maezawa, K., Hayashi, T., Sandoh, M., Ishii, M., Tasaka, S., Kanayama, A., Kobayashi, I., Betsuyaku, T., Kizu, J., Iwata, S., Sato, Y., & Hasegawa, N. (2014). The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly. Journal of Infection and Chemotherapy, 20(6), 356-360. https://doi.org/10.1016/j.jiac.2013.12.010

Namkoong, H, Kameyama, Y, Yasuda, H, Nakayama, S, Kaneko, H, Kawashima, C, Terajima, T, Maezawa, K, Hayashi, T, Sandoh, M, Ishii, M, Tasaka, S, Kanayama, A, Kobayashi, I, Betsuyaku, T, Kizu, J, Iwata, S, Sato, Y & Hasegawa, N 2014, 'The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly', Journal of Infection and Chemotherapy, vol. 20, no. 6, pp. 356-360. https://doi.org/10.1016/j.jiac.2013.12.010

@article{6b3d8a49abae4e788cda181f9da386d0,

title = "The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly",

abstract = "Biapenem has been widely used to treat bacterial pneumonia; however, there is little information concerning its efficacy and safety in elderly patients. Based on pharmacokinetic-pharmacodynamic theory, administration of biapenem thrice rather than twice daily would be expected to be more effective because of longer time above the minimum inhibitory concentration. In this study, we aimed to evaluate the efficacy, safety, and pharmacokinetics of biapenem (300 mg) administered thrice daily in pneumonic patients aged 65 years or older. Biapenem was effective in 22 of 25 patients, as assessed by the improvement in clinical symptoms and/or the eradication of the causative organisms, and caused no serious adverse events. The pharmacokinetic profile was established based on simulations using a modeling program. Among 17 patients whose causative organisms were detected, time above the minimum inhibitory concentration was estimated to be 100% in 16 patients, all of whom showed clinical improvement. The results of this study confirmed the efficacy and safety of 300 mg of biapenem administered thrice daily for the treatment of pneumonia in elderly patients.",

keywords = "Biapenem, Elderly patients, Pharmacokinetics-pharmacodynamics (PK-PD), Pneumonia",

author = "Ho Namkoong and Youjyu Kameyama and Hiroyuki Yasuda and Sohei Nakayama and Hiroshi Kaneko and Chieko Kawashima and Tomoko Terajima and Kayoko Maezawa and Takeshi Hayashi and Mitsuru Sandoh and Makoto Ishii and Sadatomo Tasaka and Akiko Kanayama and Intetsu Kobayashi and Tomoko Betsuyaku and Junko Kizu and Satoshi Iwata and Yoshitake Sato and Naoki Hasegawa",

year = "2014",

month = jun,

doi = "10.1016/j.jiac.2013.12.010",

language = "English",

volume = "20",

pages = "356--360",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly

AU - Namkoong, Ho

AU - Kameyama, Youjyu

AU - Yasuda, Hiroyuki

AU - Nakayama, Sohei

AU - Kaneko, Hiroshi

AU - Kawashima, Chieko

AU - Terajima, Tomoko

AU - Maezawa, Kayoko

AU - Hayashi, Takeshi

AU - Sandoh, Mitsuru

AU - Ishii, Makoto

AU - Tasaka, Sadatomo

AU - Kanayama, Akiko

AU - Kobayashi, Intetsu

AU - Betsuyaku, Tomoko

AU - Kizu, Junko

AU - Iwata, Satoshi

AU - Sato, Yoshitake

AU - Hasegawa, Naoki

PY - 2014/6

Y1 - 2014/6

N2 - Biapenem has been widely used to treat bacterial pneumonia; however, there is little information concerning its efficacy and safety in elderly patients. Based on pharmacokinetic-pharmacodynamic theory, administration of biapenem thrice rather than twice daily would be expected to be more effective because of longer time above the minimum inhibitory concentration. In this study, we aimed to evaluate the efficacy, safety, and pharmacokinetics of biapenem (300 mg) administered thrice daily in pneumonic patients aged 65 years or older. Biapenem was effective in 22 of 25 patients, as assessed by the improvement in clinical symptoms and/or the eradication of the causative organisms, and caused no serious adverse events. The pharmacokinetic profile was established based on simulations using a modeling program. Among 17 patients whose causative organisms were detected, time above the minimum inhibitory concentration was estimated to be 100% in 16 patients, all of whom showed clinical improvement. The results of this study confirmed the efficacy and safety of 300 mg of biapenem administered thrice daily for the treatment of pneumonia in elderly patients.

AB - Biapenem has been widely used to treat bacterial pneumonia; however, there is little information concerning its efficacy and safety in elderly patients. Based on pharmacokinetic-pharmacodynamic theory, administration of biapenem thrice rather than twice daily would be expected to be more effective because of longer time above the minimum inhibitory concentration. In this study, we aimed to evaluate the efficacy, safety, and pharmacokinetics of biapenem (300 mg) administered thrice daily in pneumonic patients aged 65 years or older. Biapenem was effective in 22 of 25 patients, as assessed by the improvement in clinical symptoms and/or the eradication of the causative organisms, and caused no serious adverse events. The pharmacokinetic profile was established based on simulations using a modeling program. Among 17 patients whose causative organisms were detected, time above the minimum inhibitory concentration was estimated to be 100% in 16 patients, all of whom showed clinical improvement. The results of this study confirmed the efficacy and safety of 300 mg of biapenem administered thrice daily for the treatment of pneumonia in elderly patients.

KW - Biapenem

KW - Elderly patients

KW - Pharmacokinetics-pharmacodynamics (PK-PD)

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=84903702022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903702022&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2013.12.010

DO - 10.1016/j.jiac.2013.12.010

M3 - Article

C2 - 24725621

AN - SCOPUS:84903702022

SN - 1341-321X

VL - 20

SP - 356

EP - 360

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

IS - 6

ER -

The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this